W
WAVEMAN · COMPANY
QNRX · Quoin Pharmaceuticals, Ltd.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

QNRX

Quoin Pharmaceuticals, Ltd.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001671502
CLUSTER · 4 INSIDERSC-SUITE BUYING · 3☆ WATCH
INSIDER NET · 180D
$280.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
4
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
10
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$280.0K over 180 days
+$280.0K over 90 days
more than 81% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
10 funds added or opened last quarter
below 82% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
4 insiders independently bought a net $280.0K while the stock fell 16% over six months — no planned sales are queued against it.
2 trial completion dates slipped in the last 90 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -4.5%
-4.5%12M
-57%+26%+110%+193%2025-092025-102025-122026-032026-052026-072026-09 2025-10-14 · LANGER DENNIS bought $128.6K2026-08-31 · Carter Denise P. bought $100.0K2026-08-31 · Myers Michael bought $100.0K2026-08-31 · Lawlor Sally Bridget bought $50.0K2026-08-31 · Culverwell Anthony James bought $30.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
4 insiders reported buying shares.
The record shows a net $280.0K bought by insiders over 180 days, 10 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Quoin Pharmaceuticals, Ltd. insiders bought a net $280.0K of stock across 23 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Culverwell Anthony James
Director
BUY
2026-08-31
6,146.0
$30.0K
Lawlor Sally Bridget
Chief Financial Officer
BUY
2026-08-31
10,244.0
$50.0K
Carter Denise P.
Chief Operating Officer
BUY
2026-08-31
20,490.0
$100.0K
Myers Michael
Chief Executive Officer
BUY
2026-08-31
20,490.0
$100.0K
LANGER DENNIS
Director
BUY
2025-10-14
15,152.0
$128.6K
23 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 18 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Stonepine Capital Management, LLC
965,032.0 sh
$3.0M
Dauntless Investment Group, LLC
214,987.0 sh
$1.0M
Ikarian Capital, LLC
211,538.0 sh
$1.0M
MILLENNIUM MANAGEMENT LLC
112,323.0 sh
$543.6K
SummitTX Capital, L.P.
100,300.0 sh
$485.5K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release
4
Multi-phase
4 ACTIVE
What changed recently
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
2026-09-01 · Completion moved 2026-07-30 → 2026-12-30
PHASE2,PHASE3
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndro
2026-09-01 · Completion moved 2025-12-30 → 2026-12-30
PHASE2,PHASE3
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
NET INCOME$-15.8M$-9.0M$-8.7M$-9.4M
OPERATING CASH FLOW$-13.5M$-7.9M$-7.9M$-8.5M
CASH$3.8M$3.6M$2.4M$2.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →